4.4 Article

Fibromyalgia and Chronic Pain Syndromes A White Paper Detailing Current Challenges in the Field

Journal

CLINICAL JOURNAL OF PAIN
Volume 32, Issue 9, Pages 737-746

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AJP.0000000000000354

Keywords

fibromyalgia; chronic widespread pain; central pain; sensory hypersensitivity; central amplification; central sensitivity syndromes; neuroimaging; regulatory pathway; unified diagnostic guidelines; interprofessional collaboration

Funding

  1. Pfizer Inc., New York, NY
  2. Dainippon Sumitomo Pharma, Tokyo, Japan
  3. Innovative Med Concepts LLC (IMC), Tuscaloosa, AL
  4. Ironwood Pharmaceuticals, Cambridge, MA
  5. Purdue Pharma, Stamford, CT
  6. Shire, Lexington, MA
  7. Theravance Biopharma, South San Francisco, CA
  8. Toray, Tokyo, Japan
  9. Eli Lilly and Company, Indianapolis, IN
  10. Forest Laboratories, New York, NY
  11. Tonix Pharmaceuticals, New York, NY
  12. Cerephex Corporation, Los Altos, CA
  13. National Institutes of Health, Bethesda, MD
  14. National Institutes of Health
  15. Grunenthal, Aachen Germany
  16. Orion Pharma, Espoo, Finland
  17. Grants-in-Aid for Scientific Research [15K15205] Funding Source: KAKEN

Ask authors/readers for more resources

This manuscript, developed by a group of chronic pain researchers and clinicians from around the world, aims to address the state of knowledge about fibromyalgia (FM) and identify ongoing challenges in the field of FM and other chronic pain syndromes that may be characterized by pain centralization/amplification/hypersensitivity. There have been many exciting developments in research studies of the pathophysiology and treatment of FM and related syndromes that have the potential to improve the recognition and management of patients with FM and other conditions with FM-like pain. However, much of the new information has not reached all clinicians, especially primary care clinicians, who have the greatest potential to use this new knowledge to positively impact their patients' lives. Furthermore, there are persistent misconceptions about FM and a lack of consensus regarding the diagnosis and treatment of FM. This paper presents a framework for future global efforts to improve the understanding and treatment of FM and other associated chronic pain syndromes, disseminate research findings, identify ways to enhance advocacy for these patients, and improve global efforts to collaborate and reach consensus about key issues related to FM and chronic pain in general.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available